Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 303

Sort by

Sort Order Select

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans

Bindiya Patel, MD, Suhong Luo, MPH, Tanya M. Wildes, MD, Kristen M. Sanfilippo, MD MPHS

Blood (2019) 134 (Supplement_1): 3478.

https://doi.org/10.1182/blood-2019-124971

Published: 2019

Journal Articles

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Clare Oni, MD, Mufaddal Moonim, MD, Joana Desterro, MD, Clive Grattan, MD, Natalia Curto-Garcia, MD, Claire Woodley, Monika Ciesielska, Deimante Drasutyte, Yvonne Francis, Jennifer O'Sullivan, MD, Thompson Olaoni, Anna Green, MD, Miki Yurina, MD, Mark Ong, MD, Nick C.P. Cross, Professor, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, Deepti Radia

Blood (2019) 134 (Supplement_1): 2960.

https://doi.org/10.1182/blood-2019-130477

Published: 2019

Journal Articles

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Ralph V. Boccia, MD, Naomi V Dahl, PharmD, William E Strauss, MD

Blood (2019) 134 (Supplement_1): 2236.

https://doi.org/10.1182/blood-2019-126149

Published: 2019

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Edward Simpson, PhD, Judith L Anderson, BS, Xiang-Qun Xie, PhDMD,MBA, Yunlong Liu, PhD, John Chirgwin, PhD, G. David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4391.

https://doi.org/10.1182/blood-2019-131865

Published: 2019

Journal Articles

No Decrease in Fracture Risk Despite 15 Years of Treatment Evolution in Multiple Myeloma Patients: A Danish Nationwide Case-Control Study

Berdien Oortgiesen, Annemariek Driessen, Mels Hoogendoorn, Dr., Robby Kibbelaar, Dr., Nic Veeger, Dr., Joop van der Bergh, Peter Vestergaard, Frank de Vries, Eric van Roon, Prof. Dr.

Blood (2019) 134 (Supplement_1): 5503.

https://doi.org/10.1182/blood-2019-122563

Published: 2019

Journal Articles

BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity

Carla E Cano, PhD, Christine Pasero, Aude De Gassart, René Hoet, Emmanuel Scotet, Erwan Mortier, Agnes Quemeneur, Chirine Rafia, Antoine Briantais, Anne-Charlotte Le Floch, MBBS,MSc, Daniel Olive, MD PhD

Blood (2019) 134 (Supplement_1): 1044.

https://doi.org/10.1182/blood-2019-128658

Published: 2019

Journal Articles

Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia

Hiroshi Fujiwara, MD PhD, Satoshi Okumura, Yoshihiro Miyahara, Linan Wan, Isao Tawara, MD PhD, Tatsuro Jo, MD PhD, Yuetsu Tanaka, PhD, Yoshimasa Tanaka, PhD, Hiroaki Ikeda, Hiroshi Shiku

Blood (2019) 134 (Supplement_1): 3216.

https://doi.org/10.1182/blood-2019-122412

Published: 2019

Journal Articles

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Stephen Booth, MA,MBBChir,MRCP,FRCPath, Hannah Plaschkes, Amy A Kirkwood, Adam Gibb, MBBS, Patrick Horgan, Joanna M Oladipo, Joseph Andrew Browning, DPhil,BMBCh, Usman Khan, John Willan, Julia Wolf, Arief Gunawan, MBBS, BSc, MRCP, Paul A Fields, MD PhD, Kim Linton, MBChB PhD, Claire Higham, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Jaimal Kothari, Catherine Hildyard, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 1615.

https://doi.org/10.1182/blood-2019-127374

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Myeloma bone disease: from biology findings to treatment approaches

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Meletios A. Dimopoulos

Blood (2019) 133 (14): 1534–1539.

https://doi.org/10.1182/blood-2018-11-852459

Published: 2019

Journal Articles

Zoledronic Acid Reduces Osteonecrosis and Anti-Leukemic Efficacy in Murine Models of Acute Lymphoblastic Leukemia Therapy

Laura Janke, DVM, PhD, Jieun Kim, PhD, David Jenkins, BS, Monique A Payton, BS, Mary V Relling, PharmD, Seth E Karol, MD

Blood (2018) 132 (Supplement 1): 4029.

https://doi.org/10.1182/blood-2018-99-112941

Published: 2018

Journal Articles

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood (2018) 132 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2018-99-111892

Published: 2018

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

In Vivo Evaluation of Novel Geranylgeranyl Diphosphate Synthase Inhibitors

Staci L. Haney, PhD, Yashpal S. Chhonker, PhD, Michelle L. Varney, MS, Geoffrey A. Talmon, MD, Daryl J. Murry, PharmD, Sarah A. Holstein, MD PhD

Blood (2018) 132 (Supplement 1): 215.

https://doi.org/10.1182/blood-2018-99-113007

Published: 2018

Journal Articles

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Adam J Olszewski, MD, Peter Barth, MD, John L. Reagan, MD

Blood (2018) 132 (Supplement 1): 709.

https://doi.org/10.1182/blood-2018-99-110739

Published: 2018

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

Journal Articles

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Attaya Suvannasankha, MD, Colin Crean, BS, Isaac Carrera Ochoa, G David Roodman, MD PhD, John Chirgwin, PhD

Blood (2018) 132 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2018-99-115680

Published: 2018

NARROW

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Frailty in Older Adults with Multiple Myeloma: A Study of United States Veterans

UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Targeting the p62-ZZ/N-End Rule Pathway in Multiple Myeloma Overcomes Proteasome Inhibitor-Resistance Via Induction of Necroptosis and Enhances the Bone Anabolic Effects of Proteasome Inhibitors

No Decrease in Fracture Risk Despite 15 Years of Treatment Evolution in Multiple Myeloma Patients: A Danish Nationwide Case-Control Study

BTN2A, a New Immune-Checkpoint Targeting Vg9Vd2 T Cell Cytotoxicity

Novel Cellular Immunotherapy Using Allogeneic Vγ9/δ2-T Cells Gene-Modified to Express HTLV-1 P40Tax-Specific TCR for the Treatment of Adult T Cell Leukemia

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Myeloma bone disease: from biology findings to treatment approaches

Zoledronic Acid Reduces Osteonecrosis and Anti-Leukemic Efficacy in Murine Models of Acute Lymphoblastic Leukemia Therapy

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

In Vivo Evaluation of Novel Geranylgeranyl Diphosphate Synthase Inhibitors

Use of Bone-Modifying Agents and Outcomes of Myeloma Therapy: A Population-Based Study

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

PTHrP May Contribute to Cachexia Accompanying Multiple Myeloma Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only